Surface Oncology IncNASDAQ SURF Stock Report

Surface Oncology, Inc. operates as a clinical-stage immuno-oncology company. The company is headquartered in Cambridge, Massachusetts and currently employs 60 full-time employees. The company went IPO on 2018-04-19. The firm is developing multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to enable an immunologic response and enhance outcomes for patients with cancer. The Company’s pipeline includes two wholly-owned clinical-stage programs targeting CD39 (SRF617) and IL-27 (SRF388), as well as a preclinical program focused on depleting tumor regulatory T cells through targeting CCR8 (SRF114). In addition, the Company has two partnerships with pharmaceutical companies, including a collaboration with Novartis targeting CD73 (NZV930; Phase 1) and a collaboration with GlaxoSmithKline targeting PVRIG (GSK4381562). Its novel cancer immunotherapies are designed to achieve a clinically meaningful and sustained anti-tumor response and may be used alone or in combination with other therapies.